HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Nephropathy induced by aminoglycoside — Clinical Guidelines

Overview

Aminoglycoside-induced nephropathy is a significant renal complication characterized by acute kidney injury often associated with tubular toxicity, particularly in patients with pre-existing renal impairment, volume depletion, or concurrent use of other nephrotoxic agents. 9

Diagnosis

Clinical Presentation: Acute decline in renal function, often evidenced by increased serum creatinine and decreased glomerular filtration rate (GFR). 9

Recommended Tests: Baseline and post-exposure serum creatinine levels, urine analysis for proteinuria or casts, and estimation of GFR. 9

Grading: Contrast-induced nephropathy (CIN) grading systems (e.g., RIFLE, AKIN) can be adapted for aminoglycoside-induced nephropathy to assess severity. 9

Management

First-Line Treatment: Discontinue aminoglycoside therapy if nephropathy is suspected. 9

Volume Replacement: Aggressive hydration to maintain adequate urine output and prevent further renal damage. 9

Adjunctive Treatments:

- Acetylcysteine: May have a protective role through antioxidant mechanisms, though evidence is primarily observational. 3 - Sodium-glucose cotransporter 2 inhibitors (SGLT2is): Potential nephroprotective role suggested by meta-analysis, though primarily studied in contrast-induced nephropathy context. 1 - Alprostadil: Limited evidence suggests potential benefit in preventing CIN, requiring further validation. 4

Special Populations

Elderly: Higher risk due to age-related renal decline and polypharmacy; close monitoring essential. 9

Comorbidities: Patients with pre-existing renal impairment or volume depletion are at increased risk; tailored dosing and hydration strategies recommended. 9

Key Recommendations

Discontinue Aminoglycosides if Nephropathy Suspected: Early cessation of aminoglycoside therapy in cases of suspected nephropathy to prevent further renal damage. (Evidence: Strong 9)

Aggressive Hydration: Maintain adequate hydration to mitigate nephrotoxicity. (Evidence: Moderate 9)

Monitor Renal Function Closely in High-Risk Populations: Increased vigilance in elderly patients and those with comorbidities such as pre-existing renal impairment. (Evidence: Moderate 9)

Consider Adjunctive Therapies with Caution: Use of acetylcysteine and SGLT2 inhibitors may offer protective benefits but evidence is primarily observational or derived from related contexts like contrast-induced nephropathy. (Evidence: Weak 1 3)

References

1 Fan G, Lin L, Zuo H, Yan R, Xu C. Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis. European journal of clinical pharmacology 2025. link 2 Tan J, Yu Y, He Y, Zheng J, Tan Q, Zhang X et al.. Data Mining and Analysis for Iodinated Contrast Media Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database. Clinical therapeutics 2025. link 3 Xie W, Liang X, Lin Z, Liu M, Ling Z. Latest Clinical Evidence About Effect of Acetylcysteine on Preventing Contrast-Induced Nephropathy in Patients Undergoing Angiography: A Meta-Analysis. Angiology 2021. link 4 Xu H, Wang H, Zhang C, Xiao J, Hua N, Tang X et al.. Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis. Angiology 2021. link 5 Loving V, Johnston B, Valencia E, Dupras S, Blackhurst K, Rush J et al.. Call For Help! The Importance of Role Delineation in a Standardized Contrast Media Emergency Response Protocol. Current problems in diagnostic radiology 2019. link 6 Kalaiselvan V, Sharma S, Singh GN. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India. Drug safety 2014. link 7 O'Malley RB, Cohan RH, Ellis JH, Caoili EM, Davenport MS, Dillman JR et al.. A survey on the use of premedication prior to iodinated and gadolinium-based contrast material administration. Journal of the American College of Radiology : JACR 2011. link 8 Alhosaini MN, Latta S, Riaz K, Hamdi T, Jallad B, Kheir F et al.. Contrast-induced nephropathy: current practices among cardiologists. Renal failure 2010. link 9 Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Current opinion in urology 2007. link 10 Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR. American journal of roentgenology 2001. link 11 Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997. link 12 Damiani DR, Swanson DP. Pharmacist-managed monitoring of adverse reactions to contrast media. American journal of hospital pharmacy 1994. link 13 Levin DC, Gardiner GA, Karasick S, Shaber GS, Wechsler RJ, McArdle GH et al.. Cost containment in the use of low-osmolar contrast agents: effect of guidelines, monitoring, and feedback mechanisms. Radiology 1993. link 14 Cashman JD, McCredie J, Henry DA. Intravenous contrast media: use and associated mortality. The Medical journal of Australia 1991. link

Nephropathy induced by aminoglycoside